13F Holdings
中文EN

BTMD biote Corp.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1819253 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.6%
TTM net income YoY-106.7%
TTM EPS YoY-108.9%
Revenue 3-yr CAGR-1.0%
Net income 3-yr CAGR—

Margins

Gross margin67.5%
Operating margin5.0%
Net margin-1.1%
FCF margin4.1%
EBITDA margin6.6%

Returns

ROE—
ROA-1.8%
ROIC (approx.)18.5%
Asset turnover1.68x

Leverage & solvency

Liabilities / assets156.6%
Debt / equity—
Current ratio1.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-7.26x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue3.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$192.22M$197.19M$185.36M$164.96M$139.40M
Cost of revenue$54.86M$58.13M$57.88M$54.58M$48.82M
Gross profit$137.36M$139.06M$127.48M$110.38M$90.58M
SG&A expense$101.81M$107.45M$98.83M$171.10M$49.05M
Operating income$35.55M$31.61M$28.66M-$60.72M$34.56M
Pretax income$37.58M$1.02M-$123,000$1.71M$32.91M
Income tax$5.99M$970,000$2.68M$388,000$286,000
Net income$27.05M$3.16M$3.32M-$969,000$11.11M
EBITDA$39.22M$35.19M$31.65M-$58.52M$35.96M
EPS (basic)0.860.090.13-0.12—
EPS (diluted)0.740.090.13-0.12—
Weighted avg. shares (diluted)36.67M34.27M25.71M8.06M—
Balance sheet
Cash & equivalents$24.12M$39.34M$89.00M$79.23M$26.77M
Receivables$6.87M$7.63M$6.81M$6.95M$5.23M
Inventory$19.06M$14.85M$17.31M$11.18M$9.62M
Current assets$54.67M$68.13M$122.34M$101.18M$47.09M
PP&E, net$10.75M$6.97M$1.22M$1.50M$2.33M
Goodwill$5.83M$5.83M———
Intangibles$4.27M$5.50M$0——
Total assets$107.61M$122.37M$155.29M$111.64M$54.33M
Current liabilities$44.99M$51.51M$22.21M$18.77M$17.31M
Short-term debt$6.25M$6.25M$6.25M$6.25M$5.00M
Long-term debt$95.78M$101.20M$106.63M$112.09M$31.96M
Total debt$102.03M$107.45M$112.88M$118.34M$36.96M
Total liabilities$158.01M$224.57M$191.84M$169.92M$50.20M
Shareholders' equity-$58.54M-$105.93M-$29.40M-$44.46M$4.12M
Net debt$77.91M$68.11M$23.88M$39.10M$10.20M
Shares outstanding———58.22M—
Cash flow statement
Operating cash flow$35.19M$45.24M$26.88M-$9.16M$33.72M
Capital expenditure$5.01M$6.43M$359,000$333,000$1.45M
Free cash flow$30.18M$38.81M$26.52M-$9.49M$32.27M
Investing cash flow-$6.86M-$18.80M-$2.71M-$1.84M-$3.81M
Financing cash flow-$43.55M-$76.08M-$14.38M$63.46M-$20.34M
Depreciation & amortization$3.67M$3.57M$2.99M$2.20M$1.40M
Stock-based compensation$8.92M$8.73M$9.06M$82.18M—
Dividends paid$1.73M$4.74M$8.69M$12.89M$11.40M
Share buybacks$3.37M$5.60M———

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.